Jo Caers
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in ⓘ
- Hematology 64
- Multiple Myeloma Research and Treatments 57
- Oncology 37
- Peptidase Inhibition and Analysis 10
- Cancer Treatment and Pharmacology 8
- CAR-T cell therapy research 8
- Bone health and treatments 6
- Co-authors
- Roy Heusschen (17 shared papers)Victor L. Thijssen (2 shared papers)Arjan W. Griffioen (1 shared paper)Yves Béguin (30 shared papers)Karin Vanderkerken (13 shared papers)Heinz Ludwig (12 shared papers)Hendrik De Raeve (6 shared papers)Eline Menu (9 shared papers)
In The Last Decade
Jo Caers
86 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Hematology 1.1k
- Oncology 934
- Immunology 557
- Genetics 201
- Emergency Medical Services 118
Countries citing papers authored by Jo Caers
This map shows the geographic impact of Jo Caers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo Caers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo Caers more than expected).
Fields of papers citing papers by Jo Caers
This network shows the impact of papers produced by Jo Caers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo Caers. The network helps show where Jo Caers may publish in the future.
Co-authors
The 25 scholars most cited alongside Jo Caers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 95 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma Hit paper breakdown → | 2022 | 350 |
| 2 | 2015 | 230 | |
| 3 | 2018 | 152 | |
| 4 | 2004 | 127 | |
| 5 | 2018 | 125 | |
| 6 | 2020 | 117 | |
| 7 | Extramedullary disease in multiple myeloma: a systematic literature review Hit paper breakdown → | 2022 | 111 |
| 8 | 2016 | 82 | |
| 9 | 2018 | 65 | |
| 10 | 2018 | 60 | |
| 11 | 2020 | 59 | |
| 12 | 2012 | 55 | |
| 13 | 2008 | 50 | |
| 14 | 2014 | 47 | |
| 15 | 2015 | 43 | |
| 16 | 2022 | 39 | |
| 17 | 2005 | 37 | |
| 18 | 2008 | 36 | |
| 19 | 2008 | 33 | |
| 20 | 2017 | 24 |
About Jo Caers
Jo Caers is a scholar working on Hematology, Oncology, Genetics, Immunology and Immunology and Allergy, having authored 95 papers that have together received 2.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (57 papers), Protein Degradation and Inhibitors (14 papers), Peptidase Inhibition and Analysis (10 papers), Cancer Treatment and Pharmacology (8 papers), CAR-T cell therapy research (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Cancer Mechanisms and Therapy (6 papers) and Bone health and treatments (6 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (934 citations), Immunology (557 citations), Genetics (201 citations) and Emergency Medical Services (118 citations). Jo Caers has collaborated with scholars based in Belgium, Austria and Germany. Frequent co-authors include Roy Heusschen, Victor L. Thijssen, Arjan W. Griffioen, Yves Béguin, Karin Vanderkerken, Heinz Ludwig, Hendrik De Raeve, Eline Menu, Joséphine Muller and Benjamin Van Camp. Their work appears in journals such as Blood, Journal of Hematology & Oncology, Haematologica, British Journal of Haematology and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.